Our medical care business contributes to the advancement of medical treatment worldwide via continuous innovation in various fields, including medical device systems that respond to unmet needs (such as chronic and acute renal disease, neurologic diseases and other intractable conditions), filters that improve the quality of blood transfusion products, and products that enable safe and efficient production of biotherapeutics and other medicines at the cutting edge of new drug development.
Developed based on the Asahi Kasei core technology of hollow-fiber membrane separation, our polysulfone-membrane dialyzers (artificial kidneys) feature superior biocompatibility and permeability. With distribution extending to more than 70 countries and growing, we continue to help more diabetes patients around the world enjoy a better quality of life.
Our innovative therapeutic apheresis devices enable new possibilities for the treatment of autoimmune and intractable diseases for which drugs are ineffective or unsuitable. Therapeutic apheresis is used to treat a wide range of intractable diseases such as neurological diseases, ulcerative colitis, and hepatic insufficiency. Blood is drawn from a patient and circulated through the device which removes pathogenic substances by separation or adsorption; the treated blood is then returned to the patient. We are the world’s leading producer of devices and systems for therapeutic apheresis, based on our core technologies of membrane separation and selective adsorption.
Our bioprocess products contribute to enhanced viral safety and improved productivity in biotherapeutic manufacturing processes. We manufacture a range of filters and equipment for the production of biotherapeutics and plasma derivatives. Our Planova™ virus removal filters contribute to enhanced safety in the production of plasma derivatives and biopharmaceuticals throughout the world.
We are the world’s leading manufacturer of filters for reduction of leukocytes from blood components for transfusion. By adsorbing leukocytes in an ultrafine nonwoven fiber membrane, Sepacell™ leukocyte reduction filters help to prevent adverse reactions to blood transfusion such as headache, chills, or fever. Since their launch in Europe in 1985, Sepacell™ filters have been widely used around the world, heightening the quality and safety of blood products for transfusion, and contributing to the progress of transfusion therapy.